Sierra Oncology, Inc. (SRRA) financial statements (2020 and earlier)

Company profile

Business Address 2150 ? 885 WEST GEORGIA STREET
VANCOUVER, BC V6C 3E8
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments148106100109150
Cash and cash equivalents148106100109150
Receivables0100 
Prepaid expense11010
Other current assets00000
Other undisclosed current assets11111
Total current assets:150109102110152
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment00001
Other noncurrent assets11000
Total noncurrent assets:11011
TOTAL ASSETS:151109102111153
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities510787
Accounts payable11130
Accrued liabilities19657
Employee-related liabilities3    
Debt0    
Derivative instruments and hedges, liabilities46    
Other liabilities    0
Other undisclosed current liabilities13    
Total current liabilities:6510787
Noncurrent Liabilities
Long-term debt and lease obligation05   
Long-term debt, excluding current maturities 5   
Operating lease, liability0
Total noncurrent liabilities:05   
Total liabilities:6515787
Stockholders' equity
Stockholders' equity attributable to parent869495103145
Preferred stock0    
Common stock00000
Additional paid in capital852772719685680
Accumulated deficit(766)(677)(624)(582)(534)
Total stockholders' equity:869495103145
TOTAL LIABILITIES AND EQUITY:151109102111153

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(67)(55)(43)(48)(36)
Operating loss:(67)(55)(43)(48)(36)
Nonoperating income (expense)(21)210(17)
Other nonoperating income (expense)(1)2100
Loss from continuing operations before income taxes:(88)(54)(42)(48)(53)
Income tax expense (benefit)00(0)(0)(0)
Net loss attributable to parent:(88)(53)(42)(48)(53)
Preferred stock dividends and other adjustments    (374)
Other undisclosed net loss available to common stockholders, basic    (26)
Net loss available to common stockholders, diluted:(88)(53)(42)(48)(453)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(88)(53)(42)(48)(53)
Comprehensive loss, net of tax, attributable to parent:(88)(53)(42)(48)(53)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: